Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma
18 Years
N/A
Both
Squamous Cell Carcinoma
Trial Information
Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma
The selective cyclo-oxygenase 2 (COX-2) inhibitor, celecoxib (Celebrex, Pfizer Inc.), is
being investigated as an anticancer agent in chemoprevention and adjuvant therapeutic
regimens in many organ systems including the head and neck, lung, colon, breast and bladder.
The mechanisms of action are not fully defined and, to date, there are no data regarding the
shortterm molecular effects of celecoxib treatment in human tumor tissues. These data are
important for understanding the targets and effects of COX-2 inhibitors in cancer.
Specifically, this pilot study seeks to evaluate the feasibility of determining whether
celecoxib treatment inhibits COX-2 expression, alters the intratumor eicosanoid profile,
and/or suppresses markers of proliferation and growth in human tumor tissues. In addition,
this trial aims to evaluate the feasibility of reliably measuring the effects of celecoxib
treatment on biomarkers of angiogenesis, prostaglandin metabolism and select growth factors.
The study is titled: "Molecular effects of short-term celecoxib treatment on head and neck
squamous carcinoma." In this study, 10 patients identified in the Head and Neck Surgical
Oncology clinic at MSKCC with untreated squamous cell carcinoma of the oral cavity or
oropharynx will be recruited to participate. Participation will not change the standard of
cancer care that the patients receive. At the initial office evaluation the tumor will be
biopsied. Blood and urine will also be collected. Patients will then take oral celecoxib
(400 mg) twice daily starting exactly 5 days prior to staging examination under anesthesia
or definitive resection and including the morning of surgery. The tumor will then be
re-biopsied at the time of staging examination under anesthesia or surgical resection. Blood
and urine will similarly be re-collected at that time.
Inclusion Criteria:
- Untreated squamous cell carcinoma of the oral cavity or oropharynx.
- Older than 18 years of age.
- Understand and sign informed consent.
Exclusion Criteria:
- Any prior treatment of the index cancer (chemotherapy, immunotherapy, hormonal
therapy or radiation therapy) or similar treatment of an unrelated malignancy within
6 weeks of enrollment into this study.
- Breast-feeding, pregnancy or of childbearing potential (including at least two years
post menopause) and unable to confirm adequate contraception (abstinence, IUD, birth
control pills, or spermicidal gel with diaphragm or condom) since last menses.
- History of esophageal, gastric or duodenal ulceration within 6 weeks of enrollment.
- History of acute or chronic renal disorder (blood creatinine level > 1.5 mg/dL).
- History of acute or chronic hepatic disorder or a significant bleeding disorder.
- History of chronic inflammatory disease (e.g. ulcerative colitis, Crohn's
disease,rheumatoid arthritis or pancreatitis).
- History of myocardial infarction, angina, or coronary artery disease within the past
6 months, or active cardiac disease.
- The subject is of New York Heart Association (NYHA) Class 3 or 4 cardiac status.
- Corticosteroid use within 6 weeks of enrollment, excluding topical nasal sprays.
- NSAID (including celecoxib) or aspirin (> 81 mg/day) use within 1 week of enrollment.
- History of hypersensitivity to COX-2 inhibitors, NSAIDs, salicylates, or
sulfonamides.
- Currently taking fluconazole or lithium.
- Investigational medication use within 6 weeks of enrollment or is scheduled to
receive an investigational drug during the course of the study.
- Principal Investigator deems subject to be at high risk for non-compliance.
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
• To determine feasibility of measuring molecular changes (COX-2 mRNA, eicosanoid profiles, Ki67, p-EGFR) in head and neck squamous cell carcinoma induced by short-term celecoxib treatment.
Outcome Time Frame:
6 years
Safety Issue:
No
Principal Investigator
Jay Boyle, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Memorial Sloan-Kettering Cancer Center
Authority:
United States: Institutional Review Board
Study ID:
03-147
NCT ID:
NCT00596219
Start Date:
December 2003
Completion Date:
October 2010
Related Keywords:
- Squamous Cell Carcinoma
- HEAD
- NECK
- SQUAMOUS
- CARCINOMA
- Carcinoma
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
Name | Location |
|---|
